Blog
Blog
AI-driven Advancements in Life Sciences
The momentum behind AI-driven advancements in life sciences has never been stronger, and this trend was spotlighted in Everest Group’s new 2025 PEAK Matrix® report, “Life Sciences AI and Analytics Services for Commercial PEAK Matrix® Assessment 2025.” Trinity Life Sciences is honored to be recognized as a Leader in this comprehensive assessment, a distinction rooted…
Filter posts by:
Blog
Transforming Data Operations: Adding Value with an Automated, Scalable Data Foundation
In today’s fast-paced business environment, the ability to harness data effectively can be a game-changer. Companies that can quickly integrate and analyze data from various sources are better positioned to make informed decisions, optimize operations and stay ahead of the competition. ...
Blog
5 Key Trends in Global Market Access
Key impacts on the market access and payer environment are beginning to unfold from policies enacted in 2023 and new policies enacted in 2024. To gather insights into the latest trends, Trinity Life Sciences conducted interviews with key stakeholders across various...
Blog
Is Medical Omnichannel Poised for Growth?
79% of respondents are predicting an increase in spend in Omnichannel capabilities for Medical Affairs in 2025, according to a recent TGaS survey fielded in September 2024.* This predicted increase for Medical Omnichannel indicates that there is a real need to...
Blog
Foundational Differentiation: CE Requires Efficient Operationalization of Data
What is data operationalization, and why is it important in life sciences? The ability to integrate insights from your data into your business workflows is commonly referred to as data operationalization. Throughout life sciences organizations, functional needs and behaviors have evolved,...
Blog
Integrated Data + Hyper-local + Cross‑channel = Customer Engagement
The customer is changing The landscape around life sciences is more competitive than ever, with a shorter runway to success and market dynamics (payer, competition, etc.) that are indisputably changing the role and level of influence at a customer level. These...
Blog
Early China Launch of PIASKY® in the Fight Against PNH
In February 2024, the National Medical Products Administration (NMPA), China’s drug regulator, granted priority review approval to Roche’s PIASKY (crovalimab), an injectable C5 inhibitor for the treatment of Paroxysmal Nocturnal Hemoglobinuria (PNH). PNH is a rare genetic blood disorder in which...
